Many hoped rituximab would be the panacea for all with IgG4-RD. Consistent story: it's not. In this European data: - only 56% in remission at 12m - pancreato-hepato-biliary slightly better, RPF mid-range This story isn't over. We need other options ABST0147 #ACR22 @RheumNow https://t.co/kyIYLLWM9g